Randomized trial to prevent congenital cytomegalovirus

Primary CMV infection during pregnancy carries a high risk of transmission to the fetus with the potential for severe sequelae including fetal death, premature birth, hearing loss and developmental delay. There is no universally accepted method of preventing congenital CMV. Our objective was to evaluate whether CMV hyperimmune globulin (HIG) administered to women with primary CMV during pregnancy reduces congenital infection.

Source: American Journal of Obstetrics and Gynecology - November 29, 2019 Category: OBGYN Authors: Brenna L. Hughes, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network Tags: IDSOG Abstract Source Type: research